Overview

A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor

Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This study is a phase I/II study of single drug TJ011133 and Toripalimab combine treatment forAdvanced solid tumor. This study include two stages. First stage is dose escalation and second stage is dose extension. The purpose of part A is to comfirm the MTD or MED and the clinical dose. The purpose of part B is to observe the safty, effectiveness, PK, PD and biomarker properties for effective subjects.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
I-Mab Biopharma Co. Ltd.